var data={"title":"Injectable soft tissue fillers: Temporary agents","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Injectable soft tissue fillers: Temporary agents</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/contributors\" class=\"contributor contributor_credentials\">Alastair Carruthers, FRCPC</a></dd><dd><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/contributors\" class=\"contributor contributor_credentials\">Jean Carruthers, MD, FRCSC</a></dd><dd><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/contributors\" class=\"contributor contributor_credentials\">Shannon Humphrey, MD, FRCPC, FAAD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/contributors\" class=\"contributor contributor_credentials\">Jeffrey S Dover, MD, FRCPC</a></dd><dd><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/contributors\" class=\"contributor contributor_credentials\">Charles E Butler, MD, FACS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/contributors\" class=\"contributor contributor_credentials\">Abena O Ofori, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Sep 20, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H44881949\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Soft-tissue fillers can be used alone or in combination with other aesthetic procedures to correct wrinkles and to restore tissue volume lost due to aging, lipoatrophy, or other causes. As opposed to permanent fillers, which persist indefinitely, temporary fillers are eventually resorbed by the body. Some agents, such as injectable collagen and hyaluronic acids, function primarily through a volume-filling effect. Others, including calcium hydroxylapatite and <a href=\"topic.htm?path=poly-l-lactic-acid-drug-information\" class=\"drug drug_general\">poly-L-lactic acid</a> fillers, act as scaffolds for endogenous collagen formation. </p><p>The type of defect to be treated and the desired duration of effect influence the selection of a soft tissue filler (<a href=\"image.htm?imageKey=DERM%2F71066\" class=\"graphic graphic_table graphicRef71066 \">table 1</a>). Regardless of which agent is selected, clinician familiarity with the product utilized is crucial; improper injection techniques result in poor cosmetic outcomes and an increased incidence of adverse effects. Although some adverse effects resolve spontaneously with time, other adverse effects (eg, tissue necrosis) may result in permanent sequelae, such as scarring.</p><p>The characteristics, efficacy, and adverse effects of several types of biodegradable soft tissue fillers will be reviewed here. An overview of the principles of the clinical use and complications of soft tissue fillers, as well as a discussion of permanent soft tissue fillers are available elsewhere. (See <a href=\"topic.htm?path=injectable-soft-tissue-fillers-permanent-agents\" class=\"medical medical_review\">&quot;Injectable soft tissue fillers: Permanent agents&quot;</a> and <a href=\"topic.htm?path=injectable-soft-tissue-fillers-overview-of-clinical-use\" class=\"medical medical_review\">&quot;Injectable soft tissue fillers: Overview of clinical use&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H44881956\"><span class=\"h1\">HYALURONIC ACID</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">Hyaluronic acid</a> is a naturally occurring glycosaminoglycan that is an essential component of the extracellular matrix of the dermis. The molecule plays a key role in the maintenance of skin structure and function, and its high water-binding capacity is of value for the maintenance of moisture in the skin [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/1\" class=\"abstract_t\">1</a>].</p><p>The injection of exogenous <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> into the skin effectively reduces visible signs of volume loss, while simultaneously providing a natural look and feel after treatment. These features, plus a relatively low risk for adverse effects have made hyaluronic acid-based fillers the most commonly used injectable soft tissue fillers worldwide (<a href=\"image.htm?imageKey=DERM%2F71066\" class=\"graphic graphic_table graphicRef71066 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/2\" class=\"abstract_t\">2</a>]. Although the US Food and Drug Administration (FDA) has approved hyaluronic acid fillers only for the treatment of nasolabial folds, these products have been used for a variety of other indications, including marionette lines, glabellar rhytides, age-related volume loss in the dorsal hands, and augmentation of the lip, chin, and cheeks [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/3-5\" class=\"abstract_t\">3-5</a>]. The clinical effects of treatment typically persist for 6 to 12 months (<a href=\"image.htm?imageKey=DERM%2F71066\" class=\"graphic graphic_table graphicRef71066 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/6\" class=\"abstract_t\">6</a>].</p><p class=\"headingAnchor\" id=\"H44887349\"><span class=\"h2\">Product characteristics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A shared feature of all <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> fillers is the inclusion of hyaluronic acid that is chemically altered through cross-linking, which allows the molecule to resist rapid degradation by <a href=\"topic.htm?path=hyaluronidase-drug-information\" class=\"drug drug_general\">hyaluronidase</a> and other factors in the skin. In contrast, naturally occurring or uncross-linked hyaluronic acid is degraded in skin within a few days. </p><p>Examples of the chemical processes utilized for cross-linking <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Butanediol diglycidyl ether (BDDE) cross-linking: Restylane, Perlane, and Juv&eacute;derm (multiple types)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Divinyl sulfone cross-linking: Prevelle Silk, Captique, and Hylaform</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Biscarbodiimide cross-linking: Elevess </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>1,2,7,8-diepoxyoctane cross-linking: Puragen</p><p/><p>Additional factors distinguish the <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> filling agents, including the source of hyaluronic acid and the expected duration of effect (<a href=\"image.htm?imageKey=DERM%2F71066\" class=\"graphic graphic_table graphicRef71066 \">table 1</a>). Moreover, specific gel characteristics, such as the concentration of hyaluronic acid and gel properties that affect product consistency, act in concert to determine the clinical behavior of each filling agent (<a href=\"image.htm?imageKey=DERM%2F80284\" class=\"graphic graphic_table graphicRef80284 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/1,7,8\" class=\"abstract_t\">1,7,8</a>]. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Origin </strong>&ndash; The chemical composition of <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> is similar across species. Hylaform, an older form of hyaluronic acid filler, contains hyaluronic acid derived from rooster combs. The majority of hyaluronic acid-based filling agents now contain nonanimal stabilized hyaluronic acid (NASHA) derived from the fermentation of <em>Streptococcus equi</em> bacteria. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Concentration </strong>&ndash; The total concentration of <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> in filling agents is readily available in package inserts. Provided other gel characteristics are similar, agents with higher concentrations of hyaluronic acid can be incompletely hydrated, resulting in a higher capacity for water-binding once placed in tissue [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/7\" class=\"abstract_t\">7</a>]. This can manifest as slight swelling of the product after placement in the skin [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/8\" class=\"abstract_t\">8</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Consistency and flow </strong>&ndash; Factors such as particles, gel hardness, and concentration of cross-linked <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> affect the consistency and fluidity of hyaluronic acid fillers (<a href=\"image.htm?imageKey=DERM%2F80284\" class=\"graphic graphic_table graphicRef80284 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/1,7,8\" class=\"abstract_t\">1,7,8</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Particulate versus nonparticulate gels </strong>&ndash; Large particles provide greater filling power and more resistance to degradation in tissues, which may be beneficial for the treatment of deep skin folds and rhytides and for volumizing skin [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/1\" class=\"abstract_t\">1</a>]. Products that contain large particles require larger gauge needles (eg, 27-gauge needles) for injection, as opposed to the 30-gauge needles that can be used with smaller particle agents. Perlane is an example of a large particle gel.</p><p/><p class=\"bulletIndent2\">Nonparticulate gels are characterized by a smoother consistency. Juv&eacute;derm Ultra, Ultra Plus, Voluma, Volift, and Volbella, which are nonparticulate gels, incorporate a relatively high degree of cross-linking to counterbalance the loss of filling power and product longevity that can result from the elimination of particles [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/1\" class=\"abstract_t\">1</a>]. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Gel hardness </strong>&ndash; G&rsquo; is a measure of the amount of gel displaced based upon the degree of stress applied to the gel [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/1\" class=\"abstract_t\">1</a>]. Gels with a high G&rsquo; (hard gels) exhibit greater resistance to deformation, require greater pressure to inject into the skin, and tend to provide a firmer feel under the skin. Soft gels may be beneficial for the treatment of areas with thin skin, such as the periorbital area or lips [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/1\" class=\"abstract_t\">1</a>]. Restylane and Perlane are relatively hard (higher G&rsquo;) gels.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Degree of cross-linking </strong>&ndash; The amount of uncross-linked (soluble) and cross-linked (insoluble) <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> in a gel influences gel viscosity [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/7\" class=\"abstract_t\">7</a>]. Decreasing the proportion of cross-linked hyaluronic acid contributes to a less viscous product and a smoother flow during injection, but may contribute to a shorter duration of effect [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/7,9\" class=\"abstract_t\">7,9</a>]. Decreasing the amount of cross-linked hyaluronic acid also decreases the hardness of a gel. </p><p/><p class=\"headingAnchor\" id=\"H44881970\"><span class=\"h2\">Mechanism of action</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The efficacy of <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> fillers has been primarily attributed to a space-filling effect of hyaluronic acid and water bound to hyaluronic acid molecules. However, a study that compared the histopathologic findings in forearm skin injected with a hyaluronic acid filler (Restylane) to sites injected isotonic saline found that the stimulation of collagen synthesis may contribute to treatment efficacy [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/10\" class=\"abstract_t\">10</a>]. The authors proposed that mechanical tension on fibroblasts, which has been associated with the regulation of collagen synthesis in other studies [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/11-13\" class=\"abstract_t\">11-13</a>], may contribute to the clinical effect of Restylane. Additional studies are necessary to determine whether similar findings occur with other hyaluronic acid filling agents and in facial skin. </p><p class=\"headingAnchor\" id=\"H44881984\"><span class=\"h2\">Formulations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A wide variety of <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> fillers are available (<a href=\"image.htm?imageKey=DERM%2F71066\" class=\"graphic graphic_table graphicRef71066 \">table 1</a>). The Juv&eacute;derm (Juv&eacute;derm Ultra, Juv&eacute;derm Ultra Plus, Juv&eacute;derm Ultra XC, Juv&eacute;derm Ultra Plus XC, Juv&eacute;derm Voluma XC, Juv&eacute;derm Volift, and Juv&eacute;derm Volbella XC) and Restylane (Restylane, Restylane-L, Restylane Silk, Perlane, and Perlane-L) lines are among the most commonly used products in the United States. Juv&eacute;derm Ultra and Juv&eacute;derm Ultra Plus are also known as Juv&eacute;derm 24 HV and Juv&eacute;derm 30 HV, respectively. </p><p>Examples of other <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> agents used in soft tissue filling worldwide include Belotero<sup> </sup>Balance, Elevess, Elravie, Puragen and Puragen Plus [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/14,15\" class=\"abstract_t\">14,15</a>], Prevelle Silk, Revanesse, and Teosyal. With the rise of the NASHA filling agents, use of Hylaform, an avian-derived filling agent, has declined.</p><p class=\"headingAnchor\" id=\"H44881991\"><span class=\"h2\">Efficacy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The utility of <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> filling agents for soft tissue augmentation of the nasolabial folds and other sites has been documented in multiple randomized trials, uncontrolled studies, and case reports [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/5,6,9,16-36\" class=\"abstract_t\">5,6,9,16-36</a>]. </p><p class=\"headingAnchor\" id=\"H44887654\"><span class=\"h3\">Versus bovine collagen</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Randomized trials comparing the efficacy of <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> fillers with bovine collagen, a filling agent that preceded the development of hyaluronic acid filling agents, for nasolabial folds have found superior results with hyaluronic acid fillers. Examples include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a randomized, split-face trial of 439 patients with moderate to severe nasolabial folds, patients were treated with either one of three <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> fillers (Juv&eacute;derm 30, Juv&eacute;derm Ultra, or Juv&eacute;derm Ultra Plus) or bovine collagen (Zyplast). Clinically significant improvement persisted for longer after treatment with the hyaluronic acid agents [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/24\" class=\"abstract_t\">24</a>]. Twenty-four weeks after the last treatment, 81 to 90 percent of nasolabial folds treated with the hyaluronic acid fillers maintained statistically significant improvement, compared with only 36 to 45 percent of nasolabial folds treated with bovine collagen. Treatment was well-tolerated in all groups. Juv&eacute;derm 30 is not available in the United States.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A randomized, split-face trial of 138 patients with mild to severe nasolabial folds treated with a <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> filler (Restylane) or bovine collagen (Zyplast) found that the degree of improvement at two, four, and six months after treatment was superior for the hyaluronic acid filler [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/21\" class=\"abstract_t\">21</a>]. Six months after treatment, 67 percent of patients treated with bovine collagen had returned to baseline severity, compared with 30 percent of patients treated with hyaluronic acid. Patient tolerance to the treatments was similar; local adverse events were mild to moderate and resolved within seven days in most patients.</p><p/><p class=\"headingAnchor\" id=\"H44887647\"><span class=\"h3\">Versus calcium hydroxylapatite</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The results of two randomized trials suggest that injectable calcium hydroxylapatite (Radiesse) may have a greater duration of effect than hyaluronic acid-based fillers in the treatment of nasolabial folds. (See <a href=\"#H44882068\" class=\"local\">'Calcium hydroxylapatite (Radiesse)'</a> below.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a randomized trial of 205 patients with moderate to severe nasolabial folds treated with calcium hydroxylapatite or <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> (Perlane, Juv&eacute;derm 24, or Juv&eacute;derm 24HV), significantly greater proportions of patients treated with calcium hydroxylapatite than with hyaluronic acid were improved at all time points up to eight months [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/37\" class=\"abstract_t\">37</a>]. However, the changes in wrinkle severity scores were similar among all of the products. Juv&eacute;derm 24 is not available in the United States, and Juv&eacute;derm 24 HV is equivalent to Juv&eacute;derm Ultra.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The results of a split-face randomized trial of 60 patients with moderate to severe nasolabial folds treated calcium hydroxylapatite or <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> (Restylane) found that more nasolabial folds treated with calcium hydroxylapatite remained improved 12 months after the initial injection (79 versus 43 percent) [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/38\" class=\"abstract_t\">38</a>]. In addition, at the same time point, nasolabial folds treated with calcium hydroxylapatite treated exhibited superior results significantly more often than the sides treated with hyaluronic acid (47 versus 5 percent of patients). </p><p/><p class=\"headingAnchor\" id=\"H1866561\"><span class=\"h3\">With lidocaine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Products that contain <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> have expanded the armamentarium of <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> fillers and have made the injection of these fillers far less uncomfortable. The results of several randomized trials indicate that lidocaine-containing hyaluronic acid fillers reduce patient discomfort and can be used safely without affecting product efficacy [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/39-45\" class=\"abstract_t\">39-45</a>].</p><p class=\"headingAnchor\" id=\"H1117199\"><span class=\"h3\">With botulinum toxin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Combination therapy with <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> fillers and botulinum toxin may improve the longevity of treatment results when treating sites of dynamic wrinkles, such as glabellar lines [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/18,46\" class=\"abstract_t\">18,46</a>]. Reduced deformation of the filler in the dermis as a result of botulinum-toxin induced local muscle relaxation is theorized to contribute to this finding. (See <a href=\"topic.htm?path=overview-of-botulinum-toxin-for-cosmetic-indications#H4081889\" class=\"medical medical_review\">&quot;Overview of botulinum toxin for cosmetic indications&quot;, section on 'Soft-tissue augmentation'</a>.)</p><p class=\"headingAnchor\" id=\"H44887668\"><span class=\"h2\">Use</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although some randomized trials have compared the efficacy of individual <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> fillers [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/15,22,23,47-49\" class=\"abstract_t\">15,22,23,47-49</a>], factors such as the type of defect to be corrected, treatment site, and preferred duration of effect are the most important factors to consider during treatment selection. Clinician familiarity with a product is also critical; improper injection technique can lead to poor results or adverse effects. (See <a href=\"topic.htm?path=injectable-soft-tissue-fillers-overview-of-clinical-use#H1194159\" class=\"medical medical_review\">&quot;Injectable soft tissue fillers: Overview of clinical use&quot;, section on 'Injection techniques'</a>.)</p><p>The ideal placement and depth of injection is dependent on the defect and site treated. In vivo and ex vivo pathologic studies suggest that the subcutis and deep dermis are the primary sites of deposition of <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> after injection into nasolabial folds [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/50,51\" class=\"abstract_t\">50,51</a>]. In contrast to treatment with Zyderm and CosmoDerm, overcorrection of defects is not required. </p><p>Juv&eacute;derm, Restylane, and Perlane products are supplied in prefilled syringes. The manufacturers of these agents recommend the following dose guidelines:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Juv&eacute;derm Ultra, Juv&eacute;derm Ultra Plus, Juv&eacute;derm Ultra XC, Juv&eacute;derm Ultra Plus XC, and Juv&eacute;derm Volbella XC: <strong>No more than </strong>20 mL per 60 kg of patient weight should be administered per year [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/52\" class=\"abstract_t\">52</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Restylane, Restylane-L, Perlane, and Perlane-L: Package inserts state that no more than<strong> </strong>6 mL should be administered per treatment session because the safety of injecting higher amounts has not been established [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/53\" class=\"abstract_t\">53</a>]. &#160;</p><p/><p>Hylaform should <strong>not</strong> be given to patients with allergies to avian proteins (eg, eggs or feathers). Juv&eacute;derm, Restylane, and Perlane products are contraindicated in patients with a history of anaphylaxis, multiple severe allergies, and allergies to gram positive bacterial proteins. Additionally, Restylane and Perlane are contraindicated in patients with bleeding disorders.</p><p class=\"headingAnchor\" id=\"H44881998\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most frequent adverse effects associated with <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> filling agents are transient and mild, and include pain bruising, edema, and erythema at the injection site [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/54,55\" class=\"abstract_t\">54,55</a>]. Fan-like needle use, rapid injection (&gt;0.3 <span class=\"nowrap\">mL/minute),</span> and high volume injections have been associated with increased rates of adverse effects [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/48\" class=\"abstract_t\">48</a>]. In addition, noninflammatory nodules or a bluish discoloration of the skin (secondary to the Tyndall effect) can occur when injections are placed too superficially [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/55-58\" class=\"abstract_t\">55-58</a>].</p><p>Delayed hypersensitivity and granulomatous reactions to <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> filling agents are rare [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/55,59-79\" class=\"abstract_t\">55,59-79</a>]. It is estimated that such reactions occur in only 0.02 percent of treatments. Differences in risk for delayed reactions based upon product type have been proposed based upon a retrospective study in which 17 of 400 patients (4 percent) treated with Juv&eacute;derm Volbella in the tear troughs or lips developed delayed reactions [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/80\" class=\"abstract_t\">80</a>]. Delayed reactions typically manifest as inflammatory papules or nodules that appear weeks to months after injection. </p><p>Complications such as bacterial and mycobacterial infections or vascular occlusion resulting in tissue necrosis or compromise of the retinal artery are also uncommon [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/81-86\" class=\"abstract_t\">81-86</a>]. The development of lower eyelid xanthelasmata following periorbital injection of a <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> filler has been reported in two patients; however, causality has not been confirmed [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/87\" class=\"abstract_t\">87</a>].</p><p class=\"headingAnchor\" id=\"H1117242\"><span class=\"h2\">Reversal</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Misplacement or excessive injection of <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> fillers can be treated with injection of <a href=\"topic.htm?path=hyaluronidase-drug-information\" class=\"drug drug_general\">hyaluronidase</a> [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/56,57,88-93\" class=\"abstract_t\">56,57,88-93</a>]. Hyaluronidase appears to be well tolerated; local injection site reactions occur infrequently, and urticaria, angioedema, or anaphylaxis rarely occur [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/94\" class=\"abstract_t\">94</a>]. Due to the potential for anaphylaxis, patients should be prick tested to evaluate for immediate hypersensitivity reactions prior to the injection of hyaluronidase [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/95\" class=\"abstract_t\">95</a>]. The use of hyaluronidase to reverse the effects of hyaluronic acid fillers is not approved by the FDA. The management of patients with signs of impending tissue necrosis due to vascular occlusion is reviewed separately. (See <a href=\"topic.htm?path=injectable-soft-tissue-fillers-overview-of-clinical-use#H1196285\" class=\"medical medical_review\">&quot;Injectable soft tissue fillers: Overview of clinical use&quot;, section on 'Early adverse effects'</a>.)</p><p>The optimum dosing of <a href=\"topic.htm?path=hyaluronidase-drug-information\" class=\"drug drug_general\">hyaluronidase</a> has not been established; doses reported in the literature vary from less than 5 units to 75 units per injection site. Doses of 10 units were effective for the dissolution of a hyaluronic acid-based filler (Restylane) injected into forearm skin in a randomized trial [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/93\" class=\"abstract_t\">93</a>]; doses as low as 1.5 to 3 units may also be effective [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/96\" class=\"abstract_t\">96</a>]. </p><p><a href=\"topic.htm?path=hyaluronidase-drug-information\" class=\"drug drug_general\">Hyaluronidase</a> has also been used successfully in the management of patients with <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> filler-induced granulomatous reactions, including a patient who failed to improve with intralesional and topical corticosteroids, oral <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a>, topical <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a>, and systemic antibiotic therapy [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/78,88\" class=\"abstract_t\">78,88</a>]. In a woman with multiple granulomatous nodules that developed after hyaluronic acid filler injection, reductions in nodule size, tenderness, and erythema attained with intralesional <a href=\"topic.htm?path=triamcinolone-drug-information\" class=\"drug drug_general\">triamcinolone</a> were followed by complete resolution of nodules after intralesional hyaluronidase therapy [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/78\" class=\"abstract_t\">78</a>]. Treatment with hyaluronidase has also been linked to the successful management of a patient with a presumed hyaluronic acid embolic event in the distribution of the angular artery [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/83\" class=\"abstract_t\">83</a>].</p><p class=\"headingAnchor\" id=\"H44882012\"><span class=\"h1\">COLLAGEN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>With the advent of <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> fillers, the use of collagen fillers has become uncommon and generally is no longer recommended. Collagen filling agents are associated a relatively shorter duration of effect, and skin testing is required prior to the use of bovine-derived agents. </p><p class=\"headingAnchor\" id=\"H44882068\"><span class=\"h1\">CALCIUM HYDROXYLAPATITE (RADIESSE)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The calcium hydroxylapatite filler (Radiesse; formerly known as Radiance) is composed of synthetic, uniform, and smooth <a href=\"topic.htm?path=calcium-hydroxylapatite-microspheres-drug-information\" class=\"drug drug_general\">calcium hydroxylapatite microspheres</a> suspended in an aqueous <a href=\"topic.htm?path=carboxymethylcellulose-drug-information\" class=\"drug drug_general\">carboxymethylcellulose</a> gel carrier [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/97\" class=\"abstract_t\">97</a>]. The FDA approved uses of Radiesse include the correction of moderate to severe facial folds and wrinkles such as nasolabial folds, and the correction of facial lipoatrophy in patients with human immunodeficiency virus (HIV) infection.</p><p class=\"headingAnchor\" id=\"H33951425\"><span class=\"h2\">Mechanism of action</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Once injected into the skin, the carrier gel is gradually resorbed and the remaining <a href=\"topic.htm?path=calcium-hydroxylapatite-microspheres-drug-information\" class=\"drug drug_general\">calcium hydroxylapatite microspheres</a> stimulate the local production of endogenous collagen. Eventually, the microspheres are degraded into calcium and phosphate ions and are excreted [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/98-100\" class=\"abstract_t\">98-100</a>].</p><p class=\"headingAnchor\" id=\"H44882082\"><span class=\"h2\">Efficacy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The efficacy of calcium hydroxylapatite for the treatment of nasolabial folds and other facial sites in healthy patients is supported by multiple studies [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/3,100-108\" class=\"abstract_t\">3,100-108</a>]. As an example, the benefit of this agent was evident in a cohort study of 1000 patients treated for a variety of cosmetic indications (most commonly nasolabial folds, marionette lines, and oral commissures) [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/100\" class=\"abstract_t\">100</a>]. More than 80 percent of patients in the study reported persistence of treatment benefit after 12 months. </p><p>Randomized trials comparing calcium hydroxylapatite with other temporary filling agents have also supported the efficacy of this product for nasolabial folds; calcium hydroxylapatite has exhibited greater duration of effect when compared with <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> and human collagen fillers [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/37,38,101\" class=\"abstract_t\">37,38,101</a>]. (See <a href=\"#H44887647\" class=\"local\">'Versus calcium hydroxylapatite'</a> above.)</p><p>Several uncontrolled studies have documented beneficial effects of calcium hydroxylapatite injections for HIV-associated lipoatrophy [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/102,109-113\" class=\"abstract_t\">102,109-113</a>]. In one open-label study of 100 patients with this disorder, treatment led to improvement in all patients through 12 months, and 91 percent of patients remained improved after 18 months [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/112\" class=\"abstract_t\">112</a>].</p><p class=\"headingAnchor\" id=\"H33951353\"><span class=\"h2\">Use</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Radiesse is supplied as a gel in a prefilled syringe; use of a 25 to 27 gauge needle is recommended for injection. A formulation of Radiesse that contains <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> is not available; however, premixing Radiesse with lidocaine prior to injection can be used to reduce patient discomfort [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/114\" class=\"abstract_t\">114</a>]. The depth of injection is subdermal (<a href=\"image.htm?imageKey=DERM%2F54021\" class=\"graphic graphic_figure graphicRef54021 \">figure 1</a>) and overcorrection of defects should be avoided. Massage of the treatment site immediately after injection facilitates even distribution of the product.</p><p>Treatment with Radiesse is contraindicated in patients with a history of anaphylaxis, multiple severe allergies, or known hypersensitivity to any of the product components. </p><p class=\"headingAnchor\" id=\"H44882089\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Injectable calcium hydroxylapatite is generally well tolerated [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/115\" class=\"abstract_t\">115</a>]. Injection-site reactions, including transient erythema, edema, ecchymosis, pain on injection, and pruritus are the most frequently reported side effects [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/97\" class=\"abstract_t\">97</a>]. Noninflammatory nodules secondary to aggregation of the filling agent can occur after treatment of the lips; the formation of nodules in other sites is rare [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/100,102,105,107,108\" class=\"abstract_t\">100,102,105,107,108</a>]. One retrospective study that included 349 lip augmentation patients found an incidence of nodule formation of 6 percent [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/100\" class=\"abstract_t\">100</a>]. The development of inflammatory nodules in the lip due to a foreign body reaction to calcium hydroxylapatite has also been reported [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/116\" class=\"abstract_t\">116</a>]. </p><p>Nodules can resolve over time; there is no injectable product that can be used to dissolve the product after injection. If treatment is desired, massage, needle disruption, or surgical excision can be utilized to accelerate resolution [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/100,102\" class=\"abstract_t\">100,102</a>]. In one patient, a calcium hydroxylapatite nodule disappeared following treatment with a fractional carbon dioxide laser for skin laxity [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/117\" class=\"abstract_t\">117</a>].</p><p>Vascular occlusion resulting in skin necrosis and ocular ischemia has occurred in at least one patient after injection of a calcium hydroxylapatite filler [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/118\" class=\"abstract_t\">118</a>]. The management of patients with signs of impending skin necrosis is reviewed separately. (See <a href=\"topic.htm?path=injectable-soft-tissue-fillers-overview-of-clinical-use#H1194167\" class=\"medical medical_review\">&quot;Injectable soft tissue fillers: Overview of clinical use&quot;, section on 'Side effects and complications'</a>.)</p><p>Although calcium hydroxylapatite implants are usually visible on computed tomography (CT) scans and are sometimes detectable on radiograph imaging, they do not appear to be detrimental for the interpretation of these studies [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/119,120\" class=\"abstract_t\">119,120</a>]. </p><p class=\"headingAnchor\" id=\"H2827103\"><span class=\"h2\">Large particle calcium hydroxylapatite</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Improvement in nasolabial folds and mid-facial atrophy after injection with a large particle formulation of calcium hydroxylapatite (Coaptite) has been reported in a few patients [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/121\" class=\"abstract_t\">121</a>]. FDA approval for Coaptite is limited to the treatment of urinary incontinence, and additional studies are necessary to explore the efficacy and safety of this agent as a cosmetic filler. (See <a href=\"topic.htm?path=stress-urinary-incontinence-in-women-persistent-recurrent-symptoms-after-surgical-treatment#H6172665\" class=\"medical medical_review\">&quot;Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment&quot;, section on 'Periurethral injection therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H44882103\"><span class=\"h1\">POLY-L-LACTIC ACID (SCULPTRA)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sculptra and Sculptra Aesthetic contain microparticles of <a href=\"topic.htm?path=poly-l-lactic-acid-drug-information\" class=\"drug drug_general\">poly-L-lactic acid</a> (PLLA), a biocompatible and biodegradable synthetic polymer [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/122\" class=\"abstract_t\">122</a>]. Sculptra is FDA approved for the treatment of HIV-associated lipoatrophy; Sculptra Aesthetic is approved for the correction of shallow to deep nasolabial fold contour deficiencies and other facial wrinkles. </p><p class=\"headingAnchor\" id=\"H44882110\"><span class=\"h2\">Mechanism of action</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Technically, PLLA does not &quot;fill&quot; the skin. Once injected, PLLA induces a subclinical inflammatory response that stimulates fibroblast proliferation and collagen formation, leading to a progressive increase in volume of the dermis. PLLA is gradually degraded over the course of 9 to 24 months [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/3\" class=\"abstract_t\">3</a>]. </p><p class=\"headingAnchor\" id=\"H799852\"><span class=\"h2\">Efficacy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The efficacy of PLLA for HIV-associated facial lipoatrophy is supported by randomized trials and uncontrolled studies that have demonstrated improvement in patient appearance and cutaneous thickness [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/123-136\" class=\"abstract_t\">123-136</a>]. As an example, in an uncontrolled study of 61 HIV-positive patients who were treated with PLLA every three to six weeks over a five-month period, all patients improved after treatment [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/127\" class=\"abstract_t\">127</a>]. </p><p>The utility of PLLA for nasolabial folds was established in a randomized trial of 233 patients who were given up to four treatment sessions with either PLLA or human collagen. Patients treated with PLLA exhibited statistically significant improvement in nasolabial fold severity over baseline at all study time points, and improvement was superior to collagen 3, 6, 9, and 13 months after treatment. Multiple other studies have supported the efficacy of PLLA for nasolabial folds, acne scars, facial asymmetry, and other cosmetic indications [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/133,137-147\" class=\"abstract_t\">133,137-147</a>]. Clinical improvement has been documented for up to two years after PLLA treatment in immunocompetent and HIV-positive patients [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/127,133,146\" class=\"abstract_t\">127,133,146</a>]. The duration of effect exceeds that of <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> and collagen fillers (<a href=\"image.htm?imageKey=DERM%2F71066\" class=\"graphic graphic_table graphicRef71066 \">table 1</a>).</p><p class=\"headingAnchor\" id=\"H800758\"><span class=\"h2\">Use</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sculptra and Sculptra Aesthetic must be reconstituted with sterile water at least two hours prior to injection to ensure complete hydration of the product. The injection should be placed in the deep dermis or subcutaneous fat with a 26-gauge or larger needle (<a href=\"image.htm?imageKey=DERM%2F54021\" class=\"graphic graphic_figure graphicRef54021 \">figure 1</a>). When treating the nasolabial folds, injection is usually performed in a cross-hatch (grid-like) pattern. </p><p>Because treatment results progressively improve over time, undercorrection of the defect is the goal. Of note, transient tissue edema may develop immediately after injection, resulting in the appearance of full correction. Subsequent treatments should be spaced by at least three weeks to allow for assessment of response. </p><p>Treatment should also be avoided in patients with a history of keloidal or hypertrophic scarring and patients with a known hypersensitivity to any of the product components [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/148,149\" class=\"abstract_t\">148,149</a>]. In addition, we typically avoid the use of this agent in the lip and periorbital region due to an increased likelihood for nodule formation in these areas [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/145,147\" class=\"abstract_t\">145,147</a>]. (See <a href=\"#H44882089\" class=\"local\">'Adverse effects'</a> above.)</p><p class=\"headingAnchor\" id=\"H800623\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Potential adverse effects of injection include hematoma, bruising, edema, discomfort, inflammation, and erythema [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/122\" class=\"abstract_t\">122</a>]. Another common complication is the occurrence of asymptomatic, subcutaneous papules weeks to months after treatment [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/122,150\" class=\"abstract_t\">122,150</a>]. In one series of 130 immunocompetent patients treated with PLLA, nodule formation occurred in 8.5 percent. Subcutaneous papule formation has been reported in 6 to 44 percent of patients treated for HIV-associated lipoatrophy [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/151\" class=\"abstract_t\">151</a>]. </p><p>Proper dilution of the product, avoidance of poor injection technique (eg, superficial injections, overcorrection), and manual tissue massage immediately after injection may decrease the risk for this adverse effect nodule formation [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/152\" class=\"abstract_t\">152</a>]. Nodules typically resolve spontaneously without intervention. Nodules that fail to resolve may require subcision (disruption of papules with a needle), excision, or intralesional corticosteroid therapy [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/133,148,149\" class=\"abstract_t\">133,148,149</a>]. </p><p>Delayed appearance of granulomatous reactions has also been reported in a few patients [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/147,153-155\" class=\"abstract_t\">147,153-155</a>].</p><p class=\"headingAnchor\" id=\"H801577\"><span class=\"h1\">PLATELET-RICH FIBRIN MATRIX</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Platelet-rich fibrin matrices (PRFM), which can be created through the centrifugation of blood, may have utility for cosmetic soft tissue augmentation [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/156\" class=\"abstract_t\">156</a>]. In a series of 15 patients, nasolabial wrinkle severity was significantly reduced after injection of autologous PRFM [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/157\" class=\"abstract_t\">157</a>]. The authors proposed that growth factors released from the injected platelets may have contributed to treatment benefit. Additional studies are necessary to determine the safety and efficacy of PRFM for this indication. </p><p class=\"headingAnchor\" id=\"H33951432\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A variety of injectable filling agents are available for the treatment of prominent skin lines, fat atrophy, and other contour defects involving soft tissue. Temporary fillers are composed of biodegradable ingredients, such as <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a>, collagen, calcium hydroxylapatite, and <a href=\"topic.htm?path=poly-l-lactic-acid-drug-information\" class=\"drug drug_general\">poly-L-lactic acid</a>. (See <a href=\"#H44881949\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hyaluronic acid-based fillers are the most common injectable agents used for soft tissue augmentation. A wide variety of products are commercially available. All <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> fillers contain chemically cross-linked hyaluronic acid, which allows the product to resist immediate degradation. Factors such as the defect type and location, the preferred duration of effect, and clinician expertise with specific agents determine the most appropriate choice of agent. (See <a href=\"#H44881956\" class=\"local\">'Hyaluronic acid'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Transient bruising, discomfort, edema, and erythema are the most common adverse effects associated with the injection of <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> fillers. Infrequently, patients may develop hypersensitivity reactions, granulomatous reactions, infections, or complications of vascular occlusion. (See <a href=\"#H44887668\" class=\"local\">'Use'</a> above and <a href=\"#H44881998\" class=\"local\">'Adverse effects'</a> above.)The effects of hyaluronic acid fillers diminish over time. <a href=\"topic.htm?path=hyaluronidase-drug-information\" class=\"drug drug_general\">Hyaluronidase</a> injections have been used for the removal of hyaluronic acid filling agents after improper placement. However, the safety and efficacy of hyaluronidase for this indication have not been evaluated. (See <a href=\"#H1117242\" class=\"local\">'Reversal'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Calcium hydroxylapatite is effective for the correction of soft-tissue defects, including nasolabial folds and HIV-associated lipodystrophy. Calcium hydroxylapatite is injected subdermally, and overcorrection of defects should be avoided. Adverse nodule formation after treatment is most likely to occur after injection of the lips. (See <a href=\"#H44882068\" class=\"local\">'Calcium hydroxylapatite (Radiesse)'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The effects of <a href=\"topic.htm?path=poly-l-lactic-acid-drug-information\" class=\"drug drug_general\">poly-L-lactic acid</a> are long lasting; improvement has been documented in patients treated for HIV-associated lipoatrophy and other soft tissue defects two years after treatment. Injections should be placed into the deep dermis or subcutaneous fat. Defects should be <strong>under</strong>corrected at the time of treatment. (See <a href=\"#H44882103\" class=\"local\">'Poly-L-lactic acid (Sculptra)'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Subcutaneous papules are a common adverse effect of treatment with <a href=\"topic.htm?path=poly-l-lactic-acid-drug-information\" class=\"drug drug_general\">poly-L-lactic acid</a>. In addition, treatment is not recommended for patients with a history of keloidal or hypertrophic scarring. (See <a href=\"#H800623\" class=\"local\">'Adverse effects'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/1\" class=\"nounderline abstract_t\">Beasley KL, Weiss MA, Weiss RA. Hyaluronic acid fillers: a comprehensive review. Facial Plast Surg 2009; 25:86.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/2\" class=\"nounderline abstract_t\">Bray D, Hopkins C, Roberts DN. A review of dermal fillers in facial plastic surgery. Curr Opin Otolaryngol Head Neck Surg 2010; 18:295.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/3\" class=\"nounderline abstract_t\">Hanke CW, Rohrich RJ, Busso M, et al. Facial Soft-Tissue Fillers conference: Assessing the State of the Science. J Am Acad Dermatol 2011; 64:S66.</a></li><li class=\"breakAll\">www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/GeneralandPlasticSurgeryDevicesPanel/UCM349459.pdf (Accessed on May 09, 2013).</li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/5\" class=\"nounderline abstract_t\">Cohen JL, Dayan SH, Brandt FS, et al. Systematic review of clinical trials of small- and large-gel-particle hyaluronic acid injectable fillers for aesthetic soft tissue augmentation. Dermatol Surg 2013; 39:205.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/6\" class=\"nounderline abstract_t\">Duranti F, Salti G, Bovani B, et al. Injectable hyaluronic acid gel for soft tissue augmentation. A clinical and histological study. Dermatol Surg 1998; 24:1317.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/7\" class=\"nounderline abstract_t\">Tezel A, Fredrickson GH. The science of hyaluronic acid dermal fillers. J Cosmet Laser Ther 2008; 10:35.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/8\" class=\"nounderline abstract_t\">Kablik J, Monheit GD, Yu L, et al. Comparative physical properties of hyaluronic acid dermal fillers. Dermatol Surg 2009; 35 Suppl 1:302.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/9\" class=\"nounderline abstract_t\">Pinsky MA, Thomas JA, Murphy DK, et al. Juv&eacute;derm injectable gel: a multicenter, double-blind, randomized study of safety and effectiveness. Aesthet Surg J 2008; 28:17.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/10\" class=\"nounderline abstract_t\">Wang F, Garza LA, Kang S, et al. In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermal filler injections in photodamaged human skin. Arch Dermatol 2007; 143:155.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/11\" class=\"nounderline abstract_t\">Varani J, Schuger L, Dame MK, et al. Reduced fibroblast interaction with intact collagen as a mechanism for depressed collagen synthesis in photodamaged skin. J Invest Dermatol 2004; 122:1471.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/12\" class=\"nounderline abstract_t\">Lambert CA, Colige AC, Lapi&egrave;re CM, Nusgens BV. Coordinated regulation of procollagens I and III and their post-translational enzymes by dissipation of mechanical tension in human dermal fibroblasts. Eur J Cell Biol 2001; 80:479.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/13\" class=\"nounderline abstract_t\">Kessler D, Dethlefsen S, Haase I, et al. Fibroblasts in mechanically stressed collagen lattices assume a &quot;synthetic&quot; phenotype. J Biol Chem 2001; 276:36575.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/14\" class=\"nounderline abstract_t\">Kinney BM. Injecting Puragen Plus into the nasolabial folds: preliminary observations of FDA trial. Aesthet Surg J 2006; 26:741.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/15\" class=\"nounderline abstract_t\">Onesti M, Toscani M, Curinga G, et al. Assessment of a new hyaluronic acid filler. double-blind, randomized, comparative study between Puragen and Captique in the treatment of nasolabial folds. In Vivo 2009; 23:479.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/16\" class=\"nounderline abstract_t\">Matarasso SL, Carruthers JD, Jewell ML, Restylane Consensus Group. Consensus recommendations for soft-tissue augmentation with nonanimal stabilized hyaluronic acid (Restylane). Plast Reconstr Surg 2006; 117:3S.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/17\" class=\"nounderline abstract_t\">Carruthers J, Carruthers A, Maberley D. Deep resting glabellar rhytides respond to BTX-A and Hylan B. Dermatol Surg 2003; 29:539.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/18\" class=\"nounderline abstract_t\">Carruthers J, Carruthers A. A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-A. Dermatol Surg 2003; 29:802.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/19\" class=\"nounderline abstract_t\">Bosniak S, Cantisano-Zilkha M, Glavas IP. Nonanimal stabilized hyaluronic acid for lip augmentation and facial rhytid ablation. Arch Facial Plast Surg 2004; 6:379.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/20\" class=\"nounderline abstract_t\">Carruthers J, Klein AW, Carruthers A, et al. Safety and efficacy of nonanimal stabilized hyaluronic acid for improvement of mouth corners. Dermatol Surg 2005; 31:276.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/21\" class=\"nounderline abstract_t\">Narins RS, Brandt F, Leyden J, et al. A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg 2003; 29:588.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/22\" class=\"nounderline abstract_t\">Carruthers A, Carey W, De Lorenzi C, et al. Randomized, double-blind comparison of the efficacy of two hyaluronic acid derivatives, restylane perlane and hylaform, in the treatment of nasolabial folds. Dermatol Surg 2005; 31:1591.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/23\" class=\"nounderline abstract_t\">Rao J, Chi GC, Goldman MP. Clinical comparison between two hyaluronic acid-derived fillers in the treatment of nasolabial folds: hylaform versus restylane. Dermatol Surg 2005; 31:1587.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/24\" class=\"nounderline abstract_t\">Baumann LS, Shamban AT, Lupo MP, et al. Comparison of smooth-gel hyaluronic acid dermal fillers with cross-linked bovine collagen: a multicenter, double-masked, randomized, within-subject study. Dermatol Surg 2007; 33 Suppl 2:S128.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/25\" class=\"nounderline abstract_t\">Narins RS, Dayan SH, Brandt FS, Baldwin EK. Persistence and improvement of nasolabial fold correction with nonanimal-stabilized hyaluronic acid 100,000 gel particles/mL filler on two retreatment schedules: results up to 18 months on two retreatment schedules. Dermatol Surg 2008; 34 Suppl 1:S2.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/26\" class=\"nounderline abstract_t\">Grimes PE, Thomas JA, Murphy DK. Safety and effectiveness of hyaluronic acid fillers in skin of color. J Cosmet Dermatol 2009; 8:162.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/27\" class=\"nounderline abstract_t\">Schweiger ES, Riddle CC, Tonkovic-Capin V, Aires DJ. Successful treatment with injected hyaluronic acid in a patient with lip asymmetry after surgical correction of cleft lip. Dermatol Surg 2008; 34:717.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/28\" class=\"nounderline abstract_t\">Bugge H, Negaard A, Skeie L, Bergersen B. Hyaluronic acid treatment of facial fat atrophy in HIV-positive patients. HIV Med 2007; 8:475.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/29\" class=\"nounderline abstract_t\">Denton AB, Tsaparas Y. Injectable hyaluronic acid for the correction of HIV-associated facial lipoatrophy. Otolaryngol Head Neck Surg 2007; 136:563.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/30\" class=\"nounderline abstract_t\">Bechara FG, Gambichler T, Brockmeyer NH, et al. Hyaluronic acid new formulation: experience in HIV-associated facial lipoatrophy. Dermatology 2008; 217:244.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/31\" class=\"nounderline abstract_t\">DeLorenzi C, Weinberg M, Solish N, Swift A. The long-term efficacy and safety of a subcutaneously injected large-particle stabilized hyaluronic acid-based gel of nonanimal origin in esthetic facial contouring. Dermatol Surg 2009; 35 Suppl 1:313.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/32\" class=\"nounderline abstract_t\">Skeie L, Bugge H, Negaard A, Bergersen BM. Large particle hyaluronic acid for the treatment of facial lipoatrophy in HIV-positive patients: 3-year follow-up study. HIV Med 2010; 11:170.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/33\" class=\"nounderline abstract_t\">Lindqvist C, Tveten S, Bondevik BE, Fagrell D. A randomized, evaluator-blind, multicenter comparison of the efficacy and tolerability of Perlane versus Zyplast in the correction of nasolabial folds. Plast Reconstr Surg 2005; 115:282.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/34\" class=\"nounderline abstract_t\">Lupo MP, Smith SR, Thomas JA, et al. Effectiveness of Juv&eacute;derm Ultra Plus dermal filler in the treatment of severe nasolabial folds. Plast Reconstr Surg 2008; 121:289.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/35\" class=\"nounderline abstract_t\">Rzany B, Bayerl C, Bodokh I, et al. An 18-Month Follow-up, Randomized Comparison of Effectiveness and Safety of Two Hyaluronic Acid Fillers for Treatment of Moderate Nasolabial Folds. Dermatol Surg 2017; 43:58.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/36\" class=\"nounderline abstract_t\">Ho D, Jagdeo J. Safety and Efficacy of a Volumizing Hyaluronic Acid Filler for Treatment of HIV-Associated Facial Lipoatrophy. JAMA Dermatol 2017; 153:61.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/37\" class=\"nounderline abstract_t\">Moers-Carpi M, Vogt S, Santos BM, et al. A multicenter, randomized trial comparing calcium hydroxylapatite to two hyaluronic acids for treatment of nasolabial folds. Dermatol Surg 2007; 33 Suppl 2:S144.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/38\" class=\"nounderline abstract_t\">Moers-Carpi MM, Tufet JO. Calcium hydroxylapatite versus nonanimal stabilized hyaluronic acid for the correction of nasolabial folds: a 12-month, multicenter, prospective, randomized, controlled, split-face trial. Dermatol Surg 2008; 34:210.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/39\" class=\"nounderline abstract_t\">Levy PM, De Boulle K, Raspaldo H. Comparison of injection comfort of a new category of cohesive hyaluronic acid filler with preincorporated lidocaine and a hyaluronic acid filler alone. Dermatol Surg 2009; 35 Suppl 1:332.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/40\" class=\"nounderline abstract_t\">Levy PM, De Boulle K, Raspaldo H. A split-face comparison of a new hyaluronic acid facial filler containing pre-incorporated lidocaine versus a standard hyaluronic acid facial filler in the treatment of naso-labial folds. J Cosmet Laser Ther 2009; 11:169.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/41\" class=\"nounderline abstract_t\">Weinkle SH, Bank DE, Boyd CM, et al. A multi-center, double-blind, randomized controlled study of the safety and effectiveness of Juv&eacute;derm injectable gel with and without lidocaine. J Cosmet Dermatol 2009; 8:205.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/42\" class=\"nounderline abstract_t\">Raspaldo H, De Boulle K, Levy PM. Longevity of effects of hyaluronic acid plus lidocaine facial filler. J Cosmet Dermatol 2010; 9:11.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/43\" class=\"nounderline abstract_t\">Brandt F, Bank D, Cross SL, Weiss R. A lidocaine-containing formulation of large-gel particle hyaluronic acid alleviates pain. Dermatol Surg 2010; 36 Suppl 3:1876.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/44\" class=\"nounderline abstract_t\">Lupo MP, Swetman G, Waller W. The effect of lidocaine when mixed with large gel particle hyaluronic acid filler tolerability and longevity: a six-month trial. J Drugs Dermatol 2010; 9:1097.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/45\" class=\"nounderline abstract_t\">Monheit GD, Campbell RM, Neugent H, et al. Reduced pain with use of proprietary hyaluronic acid with lidocaine for correction of nasolabial folds: a patient-blinded, prospective, randomized controlled trial. Dermatol Surg 2010; 36:94.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/46\" class=\"nounderline abstract_t\">Patel MP, Talmor M, Nolan WB. Botox and collagen for glabellar furrows: advantages of combination therapy. Ann Plast Surg 2004; 52:442.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/47\" class=\"nounderline abstract_t\">Prager W, Steinkraus V. A prospective, rater-blind, randomized comparison of the effectiveness and tolerability of Belotero &reg; Basic versus Restylane &reg; for correction of nasolabial folds. Eur J Dermatol 2010; 20:748.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/48\" class=\"nounderline abstract_t\">Glogau RG, Kane MA. Effect of injection techniques on the rate of local adverse events in patients implanted with nonanimal hyaluronic acid gel dermal fillers. Dermatol Surg 2008; 34 Suppl 1:S105.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/49\" class=\"nounderline abstract_t\">Kono T, Kinney BM, Groff WF, et al. Randomized, evaluator-blind, split-face comparison study of single cross-linked versus double cross-linked hyaluronic acid in the treatment of glabellar lines. Dermatol Surg 2008; 34 Suppl 1:S25.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/50\" class=\"nounderline abstract_t\">Arlette JP, Trotter MJ. Anatomic location of hyaluronic acid filler material injected into nasolabial fold: a histologic study. Dermatol Surg 2008; 34 Suppl 1:S56.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/51\" class=\"nounderline abstract_t\">Greco TM, Elenitsas R. Localization and histological characterization of injected hyaluronic acid in excised nasolabial fold tissue. J Drugs Dermatol 2010; 9:399.</a></li><li class=\"breakAll\">www.accessdata.fda.gov/cdrh_docs/pdf11/p110033s018d.pdf (Accessed on August 12, 2016).</li><li class=\"breakAll\">www.galdermausa.com/IFU/Restylane_IFU.pdf (Accessed on August 12, 2016).</li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/54\" class=\"nounderline abstract_t\">Jordan DR. Soft-tissue fillers for wrinkles, folds and volume augmentation. Can J Ophthalmol 2003; 38:285.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/55\" class=\"nounderline abstract_t\">Requena L, Requena C, Christensen L, et al. Adverse reactions to injectable soft tissue fillers. J Am Acad Dermatol 2011; 64:1.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/56\" class=\"nounderline abstract_t\">Hirsch RJ, Narurkar V, Carruthers J. Management of injected hyaluronic acid induced Tyndall effects. Lasers Surg Med 2006; 38:202.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/57\" class=\"nounderline abstract_t\">Douse-Dean T, Jacob CI. Fast and easy treatment for reduction of the Tyndall effect secondary to cosmetic use of hyaluronic acid. J Drugs Dermatol 2008; 7:281.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/58\" class=\"nounderline abstract_t\">Sclafani AP, Fagien S. Treatment of injectable soft tissue filler complications. Dermatol Surg 2009; 35 Suppl 2:1672.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/59\" class=\"nounderline abstract_t\">Lupton JR, Alster TS. Cutaneous hypersensitivity reaction to injectable hyaluronic acid gel. Dermatol Surg 2000; 26:135.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/60\" class=\"nounderline abstract_t\">Lowe NJ, Maxwell CA, Lowe P, et al. Hyaluronic acid skin fillers: adverse reactions and skin testing. J Am Acad Dermatol 2001; 45:930.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/61\" class=\"nounderline abstract_t\">Leonhardt JM, Lawrence N, Narins RS. Angioedema acute hypersensitivity reaction to injectable hyaluronic acid. Dermatol Surg 2005; 31:577.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/62\" class=\"nounderline abstract_t\">Matarasso SL, Herwick R. Hypersensitivity reaction to nonanimal stabilized hyaluronic acid. J Am Acad Dermatol 2006; 55:128.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/63\" class=\"nounderline abstract_t\">Patel VJ, Bruck MC, Katz BE. Hypersensitivity reaction to hyaluronic acid with negative skin testing. Plast Reconstr Surg 2006; 117:92e.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/64\" class=\"nounderline abstract_t\">Arron ST, Neuhaus IM. Persistent delayed-type hypersensitivity reaction to injectable non-animal-stabilized hyaluronic acid. J Cosmet Dermatol 2007; 6:167.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/65\" class=\"nounderline abstract_t\">Bisaccia E, Lugo A, Torres O, et al. Persistent inflammatory reaction to hyaluronic acid gel: a case report. Cutis 2007; 79:388.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/66\" class=\"nounderline abstract_t\">Andr&eacute; P. Evaluation of the safety of a non-animal stabilized hyaluronic acid (NASHA -- Q-Medical, Sweden) in European countries: a retrospective study from 1997 to 2001. J Eur Acad Dermatol Venereol 2004; 18:422.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/67\" class=\"nounderline abstract_t\">Saylan Z. Facial fillers and their complications. Aesthet Surg J 2003; 23:221.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/68\" class=\"nounderline abstract_t\">Fern&aacute;ndez-Ace&ntilde;ero MJ, Zamora E, Borbujo J. Granulomatous foreign body reaction against hyaluronic acid: report of a case after lip augmentation. Dermatol Surg 2003; 29:1225.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/69\" class=\"nounderline abstract_t\">H&ouml;nig JF, Brink U, Korabiowska M. Severe granulomatous allergic tissue reaction after hyaluronic acid injection in the treatment of facial lines and its surgical correction. J Craniofac Surg 2003; 14:197.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/70\" class=\"nounderline abstract_t\">Jordan DR. Delayed inflammatory reaction to hyaluronic acid (Restylane). Ophthal Plast Reconstr Surg 2005; 21:401.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/71\" class=\"nounderline abstract_t\">Edwards PC, Fantasia JE, Iovino R. Foreign body reaction to hyaluronic acid (Restylane): an adverse outcome of lip augmentation. J Oral Maxillofac Surg 2006; 64:1296.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/72\" class=\"nounderline abstract_t\">Ghislanzoni M, Bianchi F, Barbareschi M, Alessi E. Cutaneous granulomatous reaction to injectable hyaluronic acid gel. Br J Dermatol 2006; 154:755.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/73\" class=\"nounderline abstract_t\">Al-Shraim M, Jaragh M, Geddie W. Granulomatous reaction to injectable hyaluronic acid (Restylane) diagnosed by fine needle biopsy. J Clin Pathol 2007; 60:1060.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/74\" class=\"nounderline abstract_t\">Bardazzi F, Ruffato A, Antonucci A, et al. Cutaneous granulomatous reaction to injectable hyaluronic acid gel: another case. J Dermatolog Treat 2007; 18:59.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/75\" class=\"nounderline abstract_t\">Okada S, Okuyama R, Tagami H, Aiba S. Eosinophilic granulomatous reaction after intradermal injection of hyaluronic acid. Acta Derm Venereol 2008; 88:69.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/76\" class=\"nounderline abstract_t\">Mamelak AJ, Katz TM, Goldberg LH, et al. Foreign body reaction to hyaluronic acid filler injection: in search of an etiology. Dermatol Surg 2009; 35 Suppl 2:1701.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/77\" class=\"nounderline abstract_t\">Sage RJ, Chaffins ML, Kouba DJ. Granulomatous foreign body reaction to hyaluronic acid: report of a case after melolabial fold augmentation and review of management. Dermatol Surg 2009; 35 Suppl 2:1696.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/78\" class=\"nounderline abstract_t\">Alsaad SM, Fabi SG, Goldman MP. Granulomatous reaction to hyaluronic acid: a case series and review of the literature. Dermatol Surg 2012; 38:271.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/79\" class=\"nounderline abstract_t\">Beleznay K, Carruthers JD, Carruthers A, et al. Delayed-onset nodules secondary to a smooth cohesive 20 mg/mL hyaluronic acid filler: cause and management. Dermatol Surg 2015; 41:929.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/80\" class=\"nounderline abstract_t\">Artzi O, Loizides C, Verner I, Landau M. Resistant and Recurrent Late Reaction to Hyaluronic Acid-Based Gel. Dermatol Surg 2016; 42:31.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/81\" class=\"nounderline abstract_t\">Schanz S, Schippert W, Ulmer A, et al. Arterial embolization caused by injection of hyaluronic acid (Restylane). Br J Dermatol 2002; 146:928.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/82\" class=\"nounderline abstract_t\">Peter S, Mennel S. Retinal branch artery occlusion following injection of hyaluronic acid (Restylane). Clin Exp Ophthalmol 2006; 34:363.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/83\" class=\"nounderline abstract_t\">Hirsch RJ, Cohen JL, Carruthers JD. Successful management of an unusual presentation of impending necrosis following a hyaluronic acid injection embolus and a proposed algorithm for management with hyaluronidase. Dermatol Surg 2007; 33:357.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/84\" class=\"nounderline abstract_t\">Inoue K, Sato K, Matsumoto D, et al. Arterial embolization and skin necrosis of the nasal ala following injection of dermal fillers. Plast Reconstr Surg 2008; 121:127e.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/85\" class=\"nounderline abstract_t\">Burt B, Nakra T, Isaacs DK, Goldberg RA. Alar necrosis after facial injection of hyaluronic Acid. Plast Reconstr Surg 2010; 125:199e.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/86\" class=\"nounderline abstract_t\">Bachmann F, Erdmann R, Hartmann V, et al. The spectrum of adverse reactions after treatment with injectable fillers in the glabellar region: results from the Injectable Filler Safety Study. Dermatol Surg 2009; 35 Suppl 2:1629.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/87\" class=\"nounderline abstract_t\">D'Acunto C, Pazzaglia M, Raone B, et al. Xanthelasma palpebrarum: a new adverse reaction to intradermal fillers? Br J Dermatol 2013; 168:437.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/88\" class=\"nounderline abstract_t\">Brody HJ. Use of hyaluronidase in the treatment of granulomatous hyaluronic acid reactions or unwanted hyaluronic acid misplacement. Dermatol Surg 2005; 31:893.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/89\" class=\"nounderline abstract_t\">Soparkar CN, Patrinely JR, Tschen J. Erasing restylane. Ophthal Plast Reconstr Surg 2004; 20:317.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/90\" class=\"nounderline abstract_t\">Goldberg RA, Fiaschetti D. Filling the periorbital hollows with hyaluronic acid gel: initial experience with 244 injections. Ophthal Plast Reconstr Surg 2006; 22:335.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/91\" class=\"nounderline abstract_t\">Hirsch RJ, Brody HJ, Carruthers JD. Hyaluronidase in the office: a necessity for every dermasurgeon that injects hyaluronic acid. J Cosmet Laser Ther 2007; 9:182.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/92\" class=\"nounderline abstract_t\">Pierre A, Levy PM. Hyaluronidase offers an efficacious treatment for inaesthetic hyaluronic acid overcorrection. J Cosmet Dermatol 2007; 6:159.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/93\" class=\"nounderline abstract_t\">Vartanian AJ, Frankel AS, Rubin MG. Injected hyaluronidase reduces restylane-mediated cutaneous augmentation. Arch Facial Plast Surg 2005; 7:231.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/94\" class=\"nounderline abstract_t\">Lee A, Grummer SE, Kriegel D, Marmur E. Hyaluronidase. Dermatol Surg 2010; 36:1071.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/95\" class=\"nounderline abstract_t\">Andre P, Fl&eacute;chet ML. Angioedema after ovine hyaluronidase injection for treating hyaluronic acid overcorrection. J Cosmet Dermatol 2008; 7:136.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/96\" class=\"nounderline abstract_t\">Menon H, Thomas M, D'silva J. Low dose of Hyaluronidase to treat over correction by HA filler--a case report. J Plast Reconstr Aesthet Surg 2010; 63:e416.</a></li><li class=\"breakAll\">Radiesse&reg; injectable implant: Instructions for use. Franksville, WI: BioForm Medical, Inc; 2008.</li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/98\" class=\"nounderline abstract_t\">Marmur ES, Phelps R, Goldberg DJ. Clinical, histologic and electron microscopic findings after injection of a calcium hydroxylapatite filler. J Cosmet Laser Ther 2004; 6:223.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/99\" class=\"nounderline abstract_t\">Graivier MH, Bass LS, Busso M, et al. Calcium hydroxylapatite (Radiesse) for correction of the mid- and lower face: consensus recommendations. Plast Reconstr Surg 2007; 120:55S.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/100\" class=\"nounderline abstract_t\">Tzikas TL. A 52-month summary of results using calcium hydroxylapatite for facial soft tissue augmentation. Dermatol Surg 2008; 34 Suppl 1:S9.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/101\" class=\"nounderline abstract_t\">Smith S, Busso M, McClaren M, Bass LS. A randomized, bilateral, prospective comparison of calcium hydroxylapatite microspheres versus human-based collagen for the correction of nasolabial folds. Dermatol Surg 2007; 33 Suppl 2:S112.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/102\" class=\"nounderline abstract_t\">Tzikas TL. Evaluation of the Radiance FN soft tissue filler for facial soft tissue augmentation. Arch Facial Plast Surg 2004; 6:234.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/103\" class=\"nounderline abstract_t\">Cuevas S, Rivas MP, Amini S, Weiss E. Radiesse for aesthetic soft tissue augmentation. Am J Cosmet Surg 2006; 23:190.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/104\" class=\"nounderline abstract_t\">Jacovella PF, Peiretti CB, Cunille D, et al. Long-lasting results with hydroxylapatite (Radiesse) facial filler. Plast Reconstr Surg 2006; 118:15S.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/105\" class=\"nounderline abstract_t\">Jansen DA, Graivier MH. Evaluation of a calcium hydroxylapatite-based implant (Radiesse) for facial soft-tissue augmentation. Plast Reconstr Surg 2006; 118:22S.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/106\" class=\"nounderline abstract_t\">Alam M, Yoo SS. Technique for calcium hydroxylapatite injection for correction of nasolabial fold depressions. J Am Acad Dermatol 2007; 56:285.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/107\" class=\"nounderline abstract_t\">Sadick NS, Katz BE, Roy D. A multicenter, 47-month study of safety and efficacy of calcium hydroxylapatite for soft tissue augmentation of nasolabial folds and other areas of the face. Dermatol Surg 2007; 33 Suppl 2:S122.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/108\" class=\"nounderline abstract_t\">Sklar JA, White SM. Radiance FN: a new soft tissue filler. Dermatol Surg 2004; 30:764.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/109\" class=\"nounderline abstract_t\">Comite SL, Liu JF, Balasubramanian S, Christian MA. Treatment of HIV-associated facial lipoatrophy with Radiance FN (Radiesse). Dermatol Online J 2004; 10:2.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/110\" class=\"nounderline abstract_t\">Roth JS. Restorative approaches for HIV-associated lipoatrophy. PRS Notebook 2005; 10:24.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/111\" class=\"nounderline abstract_t\">Busso M, Karlsberg PL. Cheek augmentation and rejuvenation using injectable calcium hydroxylapatite (Radiesse). Cosmet Dermatol 2006; 19:583.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/112\" class=\"nounderline abstract_t\">Silvers SL, Eviatar JA, Echavez MI, Pappas AL. Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability. Plast Reconstr Surg 2006; 118:34S.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/113\" class=\"nounderline abstract_t\">Carruthers A, Carruthers J. Evaluation of injectable calcium hydroxylapatite for the treatment of facial lipoatrophy associated with human immunodeficiency virus. Dermatol Surg 2008; 34:1486.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/114\" class=\"nounderline abstract_t\">Marmur E, Green L, Busso M. Controlled, randomized study of pain levels in subjects treated with calcium hydroxylapatite premixed with lidocaine for correction of nasolabial folds. Dermatol Surg 2010; 36:309.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/115\" class=\"nounderline abstract_t\">Bass LS, Smith S, Busso M, McClaren M. Calcium hydroxylapatite (Radiesse) for treatment of nasolabial folds: long-term safety and efficacy results. Aesthet Surg J 2010; 30:235.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/116\" class=\"nounderline abstract_t\">Sankar V, McGuff HS. Foreign body reaction to calcium hydroxylapatite after lip augmentation. J Am Dent Assoc 2007; 138:1093.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/117\" class=\"nounderline abstract_t\">Reddy KK, Brauer JA, Anolik R, et al. Calcium hydroxylapatite nodule resolution after fractional carbon dioxide laser therapy. Arch Dermatol 2012; 148:634.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/118\" class=\"nounderline abstract_t\">Sung MS, Kim HG, Woo KI, Kim YD. Ocular ischemia and ischemic oculomotor nerve palsy after vascular embolization of injectable calcium hydroxylapatite filler. Ophthal Plast Reconstr Surg 2010; 26:289.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/119\" class=\"nounderline abstract_t\">Carruthers A, Liebeskind M, Carruthers J, Forster BB. Radiographic and computed tomographic studies of calcium hydroxylapatite for treatment of HIV-associated facial lipoatrophy and correction of nasolabial folds. Dermatol Surg 2008; 34 Suppl 1:S78.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/120\" class=\"nounderline abstract_t\">Valiyaparambil J, Rengasamy K, Mallya SM. An unusual soft tissue radiopacity--radiographic appearance of a dermal filler. Br Dent J 2009; 207:211.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/121\" class=\"nounderline abstract_t\">Alam M, Havey J, Pace N, et al. Large-particle calcium hydroxylapatite injection for correction of facial wrinkles and depressions. J Am Acad Dermatol 2011; 65:92.</a></li><li class=\"breakAll\">Sculptra&reg; (injectable poly-L-lactic acid) Prescribing Information. Bridgewater, NJ: Dermik Laboratories; 2006.</li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/123\" class=\"nounderline abstract_t\">Valantin MA, Aubron-Olivier C, Ghosn J, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 2003; 17:2471.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/124\" class=\"nounderline abstract_t\">Moyle GJ, Lysakova L, Brown S, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004; 5:82.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/125\" class=\"nounderline abstract_t\">Mest DR, Humble G. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience. Dermatol Surg 2006; 32:1336.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/126\" class=\"nounderline abstract_t\">Borelli C, Kunte C, Weisenseel P, et al. Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients. Skin Pharmacol Physiol 2005; 18:273.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/127\" class=\"nounderline abstract_t\">Burgess CM, Quiroga RM. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol 2005; 52:233.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/128\" class=\"nounderline abstract_t\">Bodokh I, Simonet P. [Polylactic acid injections (Newfill) in the treatment of facial lipodystrophy in HIV-positive patients]. Ann Dermatol Venereol 2006; 133:429.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/129\" class=\"nounderline abstract_t\">Cattelan AM, Bauer U, Trevenzoli M, et al. Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy. Arch Dermatol 2006; 142:329.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/130\" class=\"nounderline abstract_t\">Moyle GJ, Brown S, Lysakova L, Barton SE. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med 2006; 7:181.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/131\" class=\"nounderline abstract_t\">Carey DL, Baker D, Rogers GD, et al. A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy. J Acquir Immune Defic Syndr 2007; 46:581.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/132\" class=\"nounderline abstract_t\">Hanke CW, Redbord KP. Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging. J Drugs Dermatol 2007; 6:123.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/133\" class=\"nounderline abstract_t\">Levy RM, Redbord KP, Hanke CW. Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: a prospective 3-year follow-up study. J Am Acad Dermatol 2008; 59:923.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/134\" class=\"nounderline abstract_t\">Narciso P, Bucciardini R, Tozzi V, et al. Immediate versus delayed surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy: a randomized open-label study. AIDS Res Hum Retroviruses 2009; 25:979.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/135\" class=\"nounderline abstract_t\">El-Beyrouty C, Huang V, Darnold CJ, Clay PG. Poly-L-lactic acid for facial lipoatrophy in HIV. Ann Pharmacother 2006; 40:1602.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/136\" class=\"nounderline abstract_t\">Mest DR, Humble GM. Retreatment with injectable poly-l-lactic acid for HIV-associated facial lipoatrophy: 24-month extension of the Blue Pacific study. Dermatol Surg 2009; 35 Suppl 1:350.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/137\" class=\"nounderline abstract_t\">Beer K. A single-center, open-label study on the use of injectable poly-L-lactic acid for the treatment of moderate to severe scarring from acne or varicella. Dermatol Surg 2007; 33 Suppl 2:S159.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/138\" class=\"nounderline abstract_t\">Onesti MG, Troccola A, Scuderi N. Volumetric correction using poly-L-lactic acid in facial asymmetry: Parry Romberg syndrome and scleroderma. Dermatol Surg 2009; 35:1368.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/139\" class=\"nounderline abstract_t\">Sadick NS, Palmisano L. Case study involving use of injectable poly-L-lactic acid (PLLA) for acne scars. J Dermatolog Treat 2009; 20:302.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/140\" class=\"nounderline abstract_t\">Sadove R. Injectable poly-L: -lactic acid: a novel sculpting agent for the treatment of dermal fat atrophy after severe acne. Aesthetic Plast Surg 2009; 33:113.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/141\" class=\"nounderline abstract_t\">Vleggaar D, Bauer U. Facial enhancement and the European experience with Sculptra (poly-l-lactic acid). J Drugs Dermatol 2004; 3:542.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/142\" class=\"nounderline abstract_t\">Woerle B, Hanke CW, Sattler G. Poly-L-lactic acid: a temporary filler for soft tissue augmentation. J Drugs Dermatol 2004; 3:385.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/143\" class=\"nounderline abstract_t\">Vleggaar D. Facial volumetric correction with injectable poly-L-lactic acid. Dermatol Surg 2005; 31:1511.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/144\" class=\"nounderline abstract_t\">Salles AG, Lotierzo PH, Gimenez R, et al. Evaluation of the poly-L-lactic acid implant for treatment of the nasolabial fold: 3-year follow-up evaluation. Aesthetic Plast Surg 2008; 32:753.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/145\" class=\"nounderline abstract_t\">Lowe NJ, Maxwell CA, Lowe P, et al. Injectable poly-l-lactic acid: 3 years of aesthetic experience. Dermatol Surg 2009; 35 Suppl 1:344.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/146\" class=\"nounderline abstract_t\">Narins RS, Baumann L, Brandt FS, et al. A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles. J Am Acad Dermatol 2010; 62:448.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/147\" class=\"nounderline abstract_t\">Palm MD, Woodhall KE, Butterwick KJ, Goldman MP. Cosmetic use of poly-l-lactic acid: a retrospective study of 130 patients. Dermatol Surg 2010; 36:161.</a></li><li class=\"breakAll\">Sculptra (injectable poly-L-lactic acid) Prescribing information. http://products.sanofi-aventis.us/sculptra/sculptra.html (Accessed on May 13, 2011).</li><li class=\"breakAll\">Sculptra Aesthetic (injectable poly-L-lactic acid) Prescribing information.http://products.sanofi-aventis.us/sculptra_aesthetic/sculptra_aesthetic.html (Accessed on May 13, 2011).</li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/150\" class=\"nounderline abstract_t\">Reszko AE, Sadick NS, Magro CM, Farber J. Late-onset subcutaneous nodules after poly-L-lactic acid injection. Dermatol Surg 2009; 35 Suppl 1:380.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/151\" class=\"nounderline abstract_t\">Barton SE, Engelhard P, Conant M. Poly-L-lactic acid for treating HIV-associated facial lipoatrophy: a review of the clinical studies. Int J STD AIDS 2006; 17:429.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/152\" class=\"nounderline abstract_t\">Narins RS. Minimizing adverse events associated with poly-L-lactic acid injection. Dermatol Surg 2008; 34 Suppl 1:S100.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/153\" class=\"nounderline abstract_t\">Wildemore JK, Jones DH. Persistent granulomatous inflammatory response induced by injectable poly-L-lactic acid for HIV lipoatrophy. Dermatol Surg 2006; 32:1407.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/154\" class=\"nounderline abstract_t\">Goldan O, Garbov-Nardini G, Regev E, et al. Late-onset infections and granuloma formation after facial polylactic acid (New-Fill) injections in women who are heavy smokers. Plast Reconstr Surg 2008; 121:336e.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/155\" class=\"nounderline abstract_t\">Alijotas-Reig J, Garcia-Gimenez V, Vilardell-Tarres M. Late-onset immune-mediated adverse effects after poly-L-lactic acid injection in non-HIV patients: clinical findings and long-term follow-up. Dermatology 2009; 219:303.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/156\" class=\"nounderline abstract_t\">Sclafani AP. Applications of platelet-rich fibrin matrix in facial plastic surgery. Facial Plast Surg 2009; 25:270.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-temporary-agents/abstract/157\" class=\"nounderline abstract_t\">Sclafani AP. Platelet-rich fibrin matrix for improvement of deep nasolabial folds. J Cosmet Dermatol 2010; 9:66.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 16399 Version 21.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H33951432\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H44881949\" id=\"outline-link-H44881949\">INTRODUCTION</a></li><li><a href=\"#H44881956\" id=\"outline-link-H44881956\">HYALURONIC ACID</a><ul><li><a href=\"#H44887349\" id=\"outline-link-H44887349\">Product characteristics</a></li><li><a href=\"#H44881970\" id=\"outline-link-H44881970\">Mechanism of action</a></li><li><a href=\"#H44881984\" id=\"outline-link-H44881984\">Formulations</a></li><li><a href=\"#H44881991\" id=\"outline-link-H44881991\">Efficacy</a><ul><li><a href=\"#H44887654\" id=\"outline-link-H44887654\">- Versus bovine collagen</a></li><li><a href=\"#H44887647\" id=\"outline-link-H44887647\">- Versus calcium hydroxylapatite</a></li><li><a href=\"#H1866561\" id=\"outline-link-H1866561\">- With lidocaine</a></li><li><a href=\"#H1117199\" id=\"outline-link-H1117199\">- With botulinum toxin</a></li></ul></li><li><a href=\"#H44887668\" id=\"outline-link-H44887668\">Use</a></li><li><a href=\"#H44881998\" id=\"outline-link-H44881998\">Adverse effects</a></li><li><a href=\"#H1117242\" id=\"outline-link-H1117242\">Reversal</a></li></ul></li><li><a href=\"#H44882012\" id=\"outline-link-H44882012\">COLLAGEN</a></li><li><a href=\"#H44882068\" id=\"outline-link-H44882068\">CALCIUM HYDROXYLAPATITE (RADIESSE)</a><ul><li><a href=\"#H33951425\" id=\"outline-link-H33951425\">Mechanism of action</a></li><li><a href=\"#H44882082\" id=\"outline-link-H44882082\">Efficacy</a></li><li><a href=\"#H33951353\" id=\"outline-link-H33951353\">Use</a></li><li><a href=\"#H44882089\" id=\"outline-link-H44882089\">Adverse effects</a></li><li><a href=\"#H2827103\" id=\"outline-link-H2827103\">Large particle calcium hydroxylapatite</a></li></ul></li><li><a href=\"#H44882103\" id=\"outline-link-H44882103\">POLY-L-LACTIC ACID (SCULPTRA)</a><ul><li><a href=\"#H44882110\" id=\"outline-link-H44882110\">Mechanism of action</a></li><li><a href=\"#H799852\" id=\"outline-link-H799852\">Efficacy</a></li><li><a href=\"#H800758\" id=\"outline-link-H800758\">Use</a></li><li><a href=\"#H800623\" id=\"outline-link-H800623\">Adverse effects</a></li></ul></li><li><a href=\"#H801577\" id=\"outline-link-H801577\">PLATELET-RICH FIBRIN MATRIX</a></li><li><a href=\"#H33951432\" id=\"outline-link-H33951432\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/16399|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/54021\" class=\"graphic graphic_figure\">- Placement of injectable soft tissue fillers</a></li></ul></li><li><div id=\"DERM/16399|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/71066\" class=\"graphic graphic_table\">- Biodegradable soft tissue fillers</a></li><li><a href=\"image.htm?imageKey=DERM/80284\" class=\"graphic graphic_table\">- Properties of hyaluronic acid fillers</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=injectable-soft-tissue-fillers-overview-of-clinical-use\" class=\"medical medical_review\">Injectable soft tissue fillers: Overview of clinical use</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=injectable-soft-tissue-fillers-permanent-agents\" class=\"medical medical_review\">Injectable soft tissue fillers: Permanent agents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-botulinum-toxin-for-cosmetic-indications\" class=\"medical medical_review\">Overview of botulinum toxin for cosmetic indications</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=stress-urinary-incontinence-in-women-persistent-recurrent-symptoms-after-surgical-treatment\" class=\"medical medical_review\">Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment</a></li></ul></div></div>","javascript":null}